Double-Strength Metal Expected to Integrate into Bone up to 20 Times
Faster
$2 Billion Dental-Implant Market is Goal
Manhattan Scientifics (Pink Sheets:MHTX) today announced that its
affiliated manufacturing partner in Albuquerque, N.M. has received Food
and Drug Administration 510(k) clearance to market Manhattan
Scientifics’ super strong titanium metal dental implants. This clearance
positions the company closer to its goal of commercializing its
technology and increasing shareholder value.
The patented new form of titanium metal originally developed by Russian
scientists in concert with scientists at the Los Alamos National
Laboratory is expected to significantly improve dental implants. Studies
have shown that bone integrates with these new metals up to 20 times
faster than with conventional metals. Patients should experience shorter
post surgery healing times and a more reliable integration of these new
implants into their body.
Manhattan Scientifics Chief Scientist Terry Lowe said, "The $2 billion
annual dental implant wholesale market is 10% the size of the market for
other medical devices (for example hips, spinal devices and
cardiovascular stents) that can benefit from the advantages of our
advanced metals."
The key manufacturers of dental implants include Nobel Biocare Holding
AG (SWX:NOBN), Straumann Holding AG (SWX:STMN), Zimmer Holdings, Inc.
(NYSE: ZMH; SWX: ZMH), DENTSPLY International, Inc. (NasdaqGS: XRAY),
Biomet, Inc. and Thommen Medical AG.
Manhattan Scientifics anticipates developing additional products based
on this new titanium metal for use in orthopedics and stents.
About Manhattan Scientifics
Manhattan Scientifics, Inc., http://www.mhtx.com,
is located in New Mexico, New York, and Montreal. It is developing and
plans to acquire technologies in a variety of environmentally friendly
energy and people-friendly industries. Copies of Manhattan Scientifics'
press releases and related investor information may also be found at http://hawkassociates.com/clients/press/?client_id=7.
This press release contains forward-looking statements. Such
forward-looking statements are subject to a number of risks, assumptions
and uncertainties that could cause the Company's actual results to
differ materially from those projected in such forward-looking
statements. Forward-looking statements speak only as of the date made
and are not guarantees of future performance. We undertake no obligation
to publicly update or revise any forward-looking statements.
Manhattan Scientifics, Inc.
Manny Tsoupanarias, Chief Executive
Officer, 918-919-0370
mtsoupanarias@manhattan-scientifics.com
or
Dr.
Terry Lowe, Chief Scientist, 505-670-8755
tlowe@metallicum.com
or
Investor
Relations:
Marvin Maslow, Chairman Emeritus, 917-923-3300
marvin@marvinmaslow.com
